Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0MUBIP
ADC Name
huMov19-3-sulfo-Mal-DM4 (DAR 8.23)
Synonyms
huMov19 3 sulfo Mal DM4 (DAR 8.23)
   Click to Show/Hide
Organization
ImmunoGen, Inc.
Drug Status
Investigative
Indication
In total 2 Indication(s)
Cervical cancer [ICD11:2C77]
Investigative
Ovarian cancer [ICD11:2C73]
Investigative
Drug-to-Antibody Ratio
8.23
Antibody Name
huMov19
  Antibody Info 
Antigen Name
Folate receptor alpha (FOLR1)
  Antigen Info 
Payload Name
Mertansine DM4
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
3-sulfo-Mal
  Linker Info 
Conjugate Type
Random conjugation through nucleophilic lysines.
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 26.41
%
KB cells
Human papillomavirus-related endocervical adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 39
%
KB cells
Human papillomavirus-related endocervical adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 85.77
%
KB cells
Human papillomavirus-related endocervical adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 26.41% (Day 20) Positive FOLR1 expression (FOLR1 +++/++)
Method Description
Conjugates of the exemplary anti-FOLR1 antibodies were tested using an established xenograft model of KB cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once on day 6 post cell inoculation with 1.1 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model KB CDX model
In Vitro Model Human papillomavirus-related endocervical adenocarcinoma KB cells CVCL_0372
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 39.00% (Day 20) Positive FOLR1 expression (FOLR1 +++/++)
Method Description
Conjugates of the exemplary anti-FOLR1 antibodies were tested using an established xenograft model of KB cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once on day 6 post cell inoculation with 2.1 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model KB CDX model
In Vitro Model Human papillomavirus-related endocervical adenocarcinoma KB cells CVCL_0372
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 85.77% (Day 20) Positive FOLR1 expression (FOLR1 +++/++)
Method Description
Conjugates of the exemplary anti-FOLR1 antibodies were tested using an established xenograft model of KB cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once on day 6 post cell inoculation with 4.5 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model KB CDX model
In Vitro Model Human papillomavirus-related endocervical adenocarcinoma KB cells CVCL_0372
References
Ref 1 Folate receptor 1 antibodies and immunoconjugates and uses thereof; 2011-09-01.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.